Spinal Cord Injury Clinical Trial
Official title:
A Pilot Study to Evaluate the Feasibility of Platelet-Rich Plasma Therapy as a Treatment for Chronic Shoulder Pain in Persons With Spinal Cord Injury
Verified date | January 2013 |
Source | Kessler Foundation |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
Shoulder pain is common in persons with spinal cord injury (SCI). It is most often caused by
overuse injuries to the muscles and tendons that can occur during wheelchair propulsion,
transfers, and other activities of daily living. Normally, shoulder pain resolves with
conservative treatments such non-steroidal anti-inflammatory drugs (e.g. aspirin, ibuprofen,
naproxen, etc.) and physical therapy. However, when these treatments fail, shoulder surgery
may be the only option.
Platelet Rich Plasma therapy, or PRP, is a treatment option for non-healing muscle and
tendon injuries such as those that cause shoulder pain in persons with SCI. Using one's own
blood, cells within the blood called "platelets" are concentrated and then re-injected into
the muscle and tendon of the shoulder. These platelets release substances known as "growth
factors" that lead to tissue healing. By concentrating the platelets we increase the growth
factors up to eight times which will promote the healing of tendons. PRP therapy has shown
promise in treating tendon and muscle injuries in able-bodied persons; however, its
effectiveness in persons with SCI is unknown. The purpose of this study is to explore the
feasibility, safety, and efficacy of PRP therapy for chronic shoulder pain in persons with
SCI. The human body has a remarkable ability to heal itself and we hypothesize that
re-injecting concentrated platelets will facilitate the natural healing process and will
reduce shoulder pain in persons with SCI.
Status | Completed |
Enrollment | 6 |
Est. completion date | November 2012 |
Est. primary completion date | November 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 60 Years |
Eligibility |
Inclusion Criteria: - The subject is male or female, 18 to 60 years of age, inclusive. - The subject has neurological impairment secondary to a spinal cord injury that occurred at least twelve (12) months prior to the Screening Visit and the level of the injury is between C6 and L5, inclusive. - The subject is non-ambulatory except for exercise purposes and uses a manual or power wheelchair as his/her primary means of mobility (> 40 hours/week). - The subject currently has chronic shoulder pain due to rotator cuff disease in spite of at least 6 months of conservative treatment. Average shoulder pain intensity during the week leading up to the Screening Visit should be at least 5 out of 10 on an 11-point numerical rating scale (NRS; 0, no pain; 10, maximum pain imaginable), in spite of a past history of completing 6 months of conservative treatment. Rotator cuff disease will be defined as pain over the anterior shoulder, with direct palpation and pain at the shoulder with provocative tests for rotator cuff disease that is confirmed by tendinopathic changes on ultrasound imaging. - The subject is able and willing to comply with the protocol. - The subject is able to and has voluntarily given informed consent prior to the performance of any study-specific procedures. Exclusion Criteria: - The subject reports prior PRP treatment in the same shoulder; - The subject reports a history of systemic disorders, such as diabetes or rheumatoid arthritis; - The subject has contra-indications to the procedure, such as infection, coagulopathy, or is currently taking anti-coagulants; - The subject reports having a glucocorticoid injection in the past 4 weeks; - The subject is pregnant (documented by a urine pregnancy test); - The subject has any medical condition, including psychiatric disease, which would interfere with the interpretation of the study results or the conduct of the study. |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Kessler Institute for Rehabilitation | West Orange | New Jersey |
Lead Sponsor | Collaborator |
---|---|
Kessler Foundation |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Numerical Rating Scale (NRS) | Shoulder pain intensity will also be assessed weekly using a numerical rating scale (NRS). Subjects will be asked to rate their average pain, most severe pain, and least severe pain during the past week using an 11-point scale (i.e. 0-10) anchored at the ends by "no pain" and "worst pain ever experienced." An 11-point NRS measure of pain intensity allows for comparison across clinical trials of chronic pain treatment and is recommended as a core outcome measure for chronic pain clinical trials. | Baseline and 4 weeks, 8 weeks, 12 weeks, and 24 weeks after the PRP treatment. | No |
Secondary | Wheelchair User's Shoulder Pain Index (WUSPI) | The WUSPI is a 15-item self-report instrument that measures shoulder pain intensity in wheelchair users during various ADLs, such as transfers, loading a wheelchair into a car, wheelchair mobility, dressing, bathing, overhead lifting, driving, performing household chores, and sleeping. Each item is scored using a 10cm visual analog scale (VAS) which is anchored at the ends with "no pain" and "worst pain ever experienced." Individual item scores are summed to arrive at a total index score, which ranges from 0 to 150. | Baseline and 4 weeks, 8 weeks, 12 weeks, and 24 weeks after the PRP treatment. | No |
Secondary | Patient Global Impression of Change | Subjects will be asked to rate on a 7-point scale overall impression following treatment as compared to the previous measurement interval. The 7-point PGIC scale (anchored by "very much improved" and "very much worse") is used to measure global treatment effect. | Baseline and 4 weeks, 8 weeks, 12 weeks, and 24 weeks after the PRP treatment. | No |
Secondary | Brief Pain Inventory interference items (BPI-I) | The Brief Pain Inventory (BPI) was developed by Cleeland, and has been used in a number of investigations of chronic pain. Its pain interference subscale has been used in several investigations of pain in SCI. In its original version the subscale (BPI-I7) consisted of 7 items measuring interference with general activity, sleep, mood, relationships, etc.). For uses with an SCI sample, in item 3 of BPI-I7, ''walking ability'' is replaced by "ability to get around." | Baseline and 4 weeks, 8 weeks, 12 weeks, and 24 weeks after the PRP treatment. | No |
Secondary | Rotator Cuff Disease Score | Baseline and at the 12-Week and 24-Weeks Follow-up Visit after the PRP treatment. | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02574572 -
Autologous Mesenchymal Stem Cells Transplantation in Cervical Chronic and Complete Spinal Cord Injury
|
Phase 1 | |
Recruiting |
NCT05941819 -
ARC Therapy to Restore Hemodynamic Stability and Trunk Control in People With Spinal Cord Injury
|
N/A | |
Completed |
NCT05265377 -
Safety and Usability of the STELO Exoskeleton in People With Acquired Brain Injury and Spinal Cord Injury
|
N/A | |
Recruiting |
NCT02331979 -
Improving Bladder Function in SCI by Neuromodulation
|
N/A | |
Completed |
NCT02777281 -
Safe and Effective Shoulder Exercise Training in Manual Wheelchair Users With SCI
|
N/A | |
Recruiting |
NCT02978638 -
Electrical Stimulation for Continence After Spinal Cord Injury
|
N/A | |
Withdrawn |
NCT02237547 -
Safety and Feasibility Study of Cell Therapy in Treatment of Spinal Cord Injury
|
Phase 1/Phase 2 | |
Completed |
NCT02262234 -
Education Interventions for Self-Management of Pain Post-SCI: A Pilot Study
|
Phase 1/Phase 2 | |
Completed |
NCT02161913 -
Comparison of Two Psycho-educational Family Group Interventions for Persons With SCI and Their Caregivers
|
N/A | |
Completed |
NCT01884662 -
Virtual Walking for Neuropathic Pain in Spinal Cord Injury
|
N/A | |
Terminated |
NCT02080039 -
Electrical Stimulation of Denervated Muscles After Spinal Cord Injury
|
N/A | |
Completed |
NCT01642901 -
Zoledronic Acid in Acute Spinal Cord Injury
|
Phase 3 | |
Completed |
NCT01471613 -
Lithium, Cord Blood Cells and the Combination in the Treatment of Acute & Sub-acute Spinal Cord Injury
|
Phase 1/Phase 2 | |
Terminated |
NCT01433159 -
Comparison of HP011-101 to Standard Care for Stage I-II Pressure Ulcers in Subjects With Spinal Cord Injury
|
Phase 2 | |
Completed |
NCT02149511 -
Longitudinal Morphometric Changes Following SCI
|
||
Completed |
NCT01467817 -
Obesity/Overweight in Persons With Early and Chronic Spinal Cord Injury (SCI)
|
N/A | |
Completed |
NCT00663663 -
Telephone Intervention for Pain Study (TIPS)
|
N/A | |
Completed |
NCT01086930 -
Early Intensive Hand Rehabilitation After Spinal Cord Injury
|
Phase 3 | |
Completed |
NCT01025609 -
Dietary Patterns and Cardiovascular (CVD) Risk in Spinal Cord Injury (SCI) Factors In Individuals With Chronic Spinal Cord Injury
|
||
Terminated |
NCT01005615 -
Patterned Functional Electrical Stimulation (FES) Ergometry of Arm and Shoulder in Individuals With Spinal Cord Injury
|
Phase 1/Phase 2 |